- Ticker
- ACET
- Price
- 2.18
- Stock movement down
- -0.07 (-3.11%)
- Company name
- Adicet Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 93.64M
- Ent value
- -125.66M
- Price/Sales
- 3.75
- Price/Book
- 0.32
- Div yield
- 1.83%
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -60.22%
- 3 year return
- -44.87%
- 5 year return
- -46.22%
- 10 year return
- -
Last updated: 2024-04-08
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ACET does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.75 |
| Price to Book | 0.32 |
| EV to Sales | -5.03 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 42.95M |
| EPS (TTM) | -2.14 |
| FCF per share (TTM) | -1.89 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 24.99M |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -90.55M |
| Net income (TTM) | -87.71M |
| EPS (TTM) | -2.14 |
| EPS (1y forward) | -1.99 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -362.35% |
| Profit margin (TTM) | -350.98% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 257.66M |
| Net receivables | 0.00 |
| Total current assets | 261.04M |
| Goodwill | 19.46M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 330.69M |
| Accounts payable | 4.40M |
| Short/Current long term debt | 21.02M |
| Total current liabilities | 19.71M |
| Total liabilities | 38.35M |
| Shareholder's equity | 292.34M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -55.37M |
| Capital expenditures (TTM) | 22.26M |
| Free cash flow (TTM) | -77.63M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -30.00% |
| Return on Assets | -26.52% |
| Return on Invested Capital | -29.75% |
| Cash Return on Invested Capital | -26.33% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.22 |
| Daily high | 2.26 |
| Daily low | 2.13 |
| Daily Volume | 646K |
| All-time high | 145.95 |
| 1y analyst estimate | 27.63 |
| Beta | 2.02 |
| EPS (TTM) | -2.14 |
| Dividend per share | 0.04 |
| Ex-div date | 21 Sep 2018 |
| Next earnings date | 7 May 2024 |
Downside potential
Loading...
Downside potential data
| ACET | S&P500 | |
| Current price drop from All-time high | -98.51% | -0.85% |
| Highest price drop | -99.24% | -56.47% |
| Date of highest drop | 28 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -80.35% | -11.35% |
| Avg time to new high | 173 days | 13 days |
| Max time to new high | 1540 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
93.64M
Marketcap category
Small-cap
Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
Employees
132
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page